Browsing Tag
Alopecia Areata
10 posts
Lilly’s Olumiant moves closer to European approval for teen alopecia patients as CHMP issues positive opinion
Eli Lilly's Olumiant wins CHMP backing for adolescent alopecia areata with 42% response rates — EU approval imminent, U.S. decision due late 2026. Read the full analysis.
Nektar Therapeutics (NASDAQ: NKTR) raises $460m as rezpegaldesleukin data strengthens Phase 3 autoimmune outlook
Nektar Therapeutics raised $460 million after strong rezpegaldesleukin data. Find out what this means for Phase 3 trials and autoimmune drug markets.
Q32 Bio divests complement inhibitor ADX-097 as Akebia Therapeutics builds rare kidney disease pipeline
Discover how Q32 Bio’s ADX-097 sale to Akebia Therapeutics reshapes both companies’ pipelines, balance sheets, and investor outlook.
Could Eli Lilly and Incyte’s Olumiant redefine how adolescent alopecia areata is treated in 2025?
Find out how Eli Lilly and Incyte's Olumiant helped teens regrow hair in a new trial—could this redefine alopecia areata treatment for adolescents?
Q32 Bio’s bempikibart shows signs of a remittive effect in alopecia areata—Here’s what that means
Q32 Bio Inc. has released promising SIGNAL-AA trial results, shedding new light on the potential of bempikibart clinical…
Sun Pharma reveals new clinical data at the 2024 EADV Congress, showing significant improvements in severe skin conditions
Sun Pharmaceutical Industries Limited has made a significant breakthrough in the treatment of severe dermatological conditions, unveiling new…
Sun Pharmaceutical bags LEQSELVI FDA approval for severe alopecia areata
In a significant development for the treatment of severe alopecia areata, Sun Pharmaceutical Industries Limited has announced that…
Sun Pharma’s NDA for Deuruxolitinib garners FDA nod: A potential leap for alopecia areata patients
Sun Pharmaceutical Industries Ltd announced that the U.S. Food and Drug Administration (FDA) has officially accepted the New…
Pfizer gets LITFULO FDA approval for severe alopecia areata
Pfizer has announced that the US Food and Drug Administration (FDA) has granted approval to LITFULO (ritlecitinib) as…
Sun Pharma to acquire Concert Pharmaceuticals to bolster dermatology franchise
India-based Sun Pharmaceutical Industries (Sun Pharma) will acquire US-based Concert Pharmaceuticals for equity consideration of $576 million to…